US2005281794A1PendingUtilityA1

Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds

48
Assignee: MATTHIAS RATHPriority: Jan 8, 2002Filed: Aug 24, 2005Published: Dec 22, 2005
Est. expiryJan 8, 2022(expired)· nominal 20-yr term from priority
Inventors:Shirang NetkeVadim IvanovWahid M. RoomiAleksandra NiedzwieckiMatthias Rath
A61P 37/08A61P 9/04A61P 43/00A61P 37/02A61P 9/10A61P 35/04A61P 25/00A61P 35/00A61P 31/10A61P 25/28A61P 29/00A61P 31/18A61P 31/04A61P 31/22A61P 31/20A61P 31/16A61P 1/02A61P 19/10A61P 1/16A61P 11/00A61P 19/02A61P 17/00A61K 31/401A61K 31/198A61K 31/385A61K 31/355A61K 31/375A61K 33/04A61K 31/525A61K 31/353
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a composition comprising a catechin compound, ascorbic acid, proline and lysine. The present invention also relates to a method for treating neoplastic disease using a composition comprising a catechin compound, ascorbic acid, proline and lysine.

Claims

exact text as granted — not AI-modified
1 . A composition of biochemical substances comprising a catechin compound, an anti-oxidant, proline and lysine that is effective in inhibiting a matrix-metalloproteinase.  
     
     
         2 . The composition according to  claim 1 , wherein the catechin compound is selected from the group consisting of epicatechins, epigallocatechin, epicatechin gallate, and epigallocatechin gallate.  
     
     
         3 . The composition according to  claim 1 , wherein the catechin compound is epigallocatechin gallate.  
     
     
         4 . The composition according to  claim 1 , wherein the anti-oxidant is selected from the group consisting of ascorbic acid, tocopherols, tocotrienols, carotinoids, glutathione, alpha-lipoic acid, ubiquinols, bioflavonoids, and carnitine.  
     
     
         5 . The composition according to  claim 1 , wherein the anti-oxidant is ascorbic acid.  
     
     
         6 . The composition according to  claim 5 , wherein the ascorbic acid is selected from the group consisting of ascorbate precursors, ascorbate metabolites and an ascorbate salt.  
     
     
         7 . The composition according to  claim 1 , wherein the anti-oxidant further comprises a folic acid.  
     
     
         8 . The composition according to  claim 7 , wherein the folic acid is folate.  
     
     
         9 . The composition according to  claim 1 , wherein the composition further comprises a selenium.  
     
     
         10 . The composition according to  claim 9 , wherein the selenium is selected from the group consisting of selinite and methyl selinate.  
     
     
         11 . The composition according to  claim 1 , wherein the matrix-metalloproteinase is selected from the group consisting of matrix-metalloproteinase  1 , matrix-metalloproteinase 2, matrix-metalloproteinase 3, matrix-metalloproteinase 4, matrix-metalloproteinase 5, matrix-metalloproteinase 6, matrix-metalloproteinase 7, matrix-metalloproteinase 8, matrix-metalloproteinase 9, matrix-metalloproteinase 10, matrix-metalloproteinase 11, matrix-metalloproteinase 12, and matrix-metalloproteinase 14.  
     
     
         12 . The composition according to  claim 1 , wherein the matrix-metalloproteinases is matrix-metalloproteinase 2.  
     
     
         13 . The composition according to  claim 1 , wherein the matrix-metalloproteinase is matrix-metalloproteinase 9.  
     
     
         14 . A method of treating human diseases associated with an elevated matrix-metalloproteinase activity by administering to a patient in need a composition of biochemical substances comprising a catechin compound, an anti-oxidant, proline and lysine that are effective in inhibiting a matrix-metalloproteinase.  
     
     
         15 . The method according to  claim 14 , wherein the catechin compound is selected from the group consisting of epicatechins, epigallocatechin, epicatechin gallate, and epigallocatechin gallate.  
     
     
         16 . The method according to  claim 14 , wherein the catechin compound is epigallocatechin gallate.  
     
     
         17 . The method according to  claim 14 , wherein the anti-oxidant is selected from the group consisting of ascorbic acid, tocopherols, tocotrienols, carotinoids, glutathione, alpha-lipoic acid, ubiquinols, bioflavonoids, and carnitine.  
     
     
         18 . The method according to  claim 14 , wherein the anti-oxidant is ascorbic acid.  
     
     
         19 . The method according to  claim 14 , wherein the ascorbic acid further comprises an ascorbate selected from the group consisting of ascorbate precursors, ascorbate metabolites and ascorbate salts.  
     
     
         20 . The method according to  claim 14 , wherein the anti-oxidant further comprises a folic acid.  
     
     
         21 - 36 . (canceled)

Join the waitlist — get patent alerts

Track US2005281794A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.